Two “new generation” drugs for the bone marrow cancer multiple myeloma may work even better together than they do individually, according to the results of a multicenter Phase I clinical trial to be presented by Dana-Farber Cancer Institute scientists at the annual meeting of the American Society of Hematology in Orlando, Fla.
Mayo Clinic Cancer Center, in collaboration with researchers from the University of Iowa, today presented results of a Phase II clinical study indicating that an oral drug, tipifarnib, can stall or reverse disease progression for patients with relapsed aggressive non-Hodgkin lymphoma.
A new report by leading experts in monoclonal antibody research for oncology offers a conceptual framework for future research in the design of antibody therapies against solid tumors.
Community based occupational therapy for elderly patients with dementia improves daily function and reduces the burden on carers say Graff and colleagues.
FDA notified healthcare professionals of revisions to the WARNINGS section of the prescribing information for Heparin to inform clinicians of the possibility of delayed onset of heparin-induced thrombocytopenia (HIT), a serious antibody-mediated reaction resulting from irreversible aggregation of platelets.
Researchers at Mayo Clinic Cancer Center, in cooperation with industry partners, have, for the first time, identified tumor specific alterations in the cellular pathway by which the multiple myeloma drug bortezomib (Velcade) works, and they have identified nine new genetic mutations in cancer cells that should increase a patient’s chance of responding to the agent.
Results from a clinical trial evaluating new drug combinations for sleeping sickness, carried out by the international humanitarian medical aid agency Medecins Sans Frontieres (MSF), and its research arm, Epicentre, have now been published in the journal PLoS Clinical Trials.
The International Myeloma Foundation (IMF) — conducting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians — today noted that multiple studies presented at the 2006 Annual Meeting of the American Society of Hematology (ASH) illustrate the breadth of the gains being made in the treatment of multiple myeloma and related blood cancers.
King Pharmaceuticals (NYSE: KG) reported today that the U.S. Food and Drug Administration (?FDA?) has approved the Company?s revised prescribing information for its Skelaxin? (metaxalone) product. Skelaxin? is a leading branded muscle relaxant, indicated as an adjunct therapy for the relief of discomforts associated with acute, painful musculoskeletal conditions. The new labeling includes revised ?Precautions? and ?Clinical Pharmacology: Pharmacokinetics? sections.
The Cabinet Committee on Economic Affairs, India today gave its approval for implementation of project entitled ?prevention of mother to child transmission of HIV/AIDS? with financial outlay of Rs.342.81 crore awarded by the Global Fund to fight AIDS, Tuberculosis and Malaria (Round II funding) as additionality over and above the provision for integrated National AIDS Control Programme (NACP).